ROS1 is an inclusion criterion in 28 clinical trials for non-small cell lung carcinoma, of which 26 are open and 2 are closed. Of the trials that contain ROS1 status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 19 are phase 2 (17 open), and 1 is phase 2/phase 3 (1 open) [4].

Cabozantinib, ceritinib, crizotinib, entrectinib, lorlatinib, and pembrolizumab have evidence of efficacy in patients with ROS1 mutation in non-small cell lung carcinoma [4].

ROS1 is an inclusion criterion in 19 clinical trials for malignant solid tumor, of which 17 are open and 2 are closed. Of the trials that contain ROS1 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 11 are phase 2 (11 open) [4].

ROS1 is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

ROS1 is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [4].

ROS1 is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain ROS1 status and cancer as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ROS1 is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ROS1 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].